Updated: 1 day ago
Medically reviewed by Dr Eric Wang-ChinaCureLink Team
Introduction
Chinese lung cancer teams now run some of the world's most closely watched trials. In the HARMONi-2 phase III trial led at Shanghai East Hospital, the Chinese-developed drug ivonescimab extended median overall survival to 30.8 months, against 22.6 months with pembrolizumab, in previously untreated advanced non-small cell lung cancer. Lung cancer is also China's most common cancer, so its leading thoracic oncologists see a volume of cases few centres elsewhere can match.
For an international patient, the practical question is how to book a lung cancer consultation in China with the right specialist, and whether that consultation can happen before boarding a plane. This guide explains which specialist to book, which records to prepare, how remote review works and what the consultation should answer.
Key Takeaways |
|
Table of Contents
Why International Patients Book a Lung Cancer Consultation in China
Three developments drive most enquiries. First, several lung cancer drugs are approved in China before, or instead of, approval elsewhere. Ivonescimab, a bispecific antibody that blocks both PD-1 and VEGF, has been approved in China since April 2025 for PD-L1-positive advanced lung cancer without EGFR or ALK alterations.
Second, China has a deep bench of EGFR expertise. EGFR mutations are far more common in East Asian patients, and Chinese investigators co-led trials that shaped global practice, including the ADAURA study of osimertinib after surgery and the FURLONG study of the Chinese-developed drug furmonertinib.
Third, minimally invasive options such as microwave ablation and cryoablation are used widely in Chinese interventional departments for patients whose tumours are considered too risky to operate on. A full overview of these options is in ChinaCureLink's guide to lung cancer treatment in China.
Choosing the Right Lung Cancer Specialist in China
Lung cancer care in a large Chinese hospital is split across departments. Booking the wrong one is the most common reason a first consultation ends with a referral rather than an answer.
If you’re still deciding which center to contact, compare China’s leading cancer hospitals by specialty alongside the lung-specific shortlist.
For patients whose disease has progressed after standard treatment, the conversation may extend to investigational options such as lung cancer TIL therapy in China or personalised cancer vaccines in the Boao Lecheng pilot zone. These are specialist questions in their own right, and not every programme accepts international patients.
The hospitals leading this work are profiled in ChinaCureLink's list of the best lung cancer hospitals in China.
Records to Prepare Before the Consultation
A Chinese specialist can only answer what the records allow. Incomplete files are the main reason a consultation produces a request for more tests rather than a plan.
Two points often surprise patients. Lung cancers, especially EGFR-mutated tumours, can change after treatment, so a Chinese specialist may ask for a new biopsy or a liquid biopsy before recommending a drug. And all records should be translated into Chinese or English by a medical translator before review, because a doctor reading an untranslated file is working blind.
Remote Review Before Travel and the In-Person Visit
China's internet-hospital regulations allow online consultations only as follow-up visits for patients already diagnosed in person. A Chinese hospital cannot make a first diagnosis or start treatment through an online visit.
This is why a well-run booking happens in two stages:
Records-based second opinion before travel. A specialist reviews the translated records and imaging, then discusses the findings with the patient by video. The output is an opinion on options and suitability, not a diagnosis or prescription.
In-person consultation in China. If the patient decides to proceed, the hospital examines the patient, repeats any tests it needs and confirms the plan.
The first stage is what saves time and money. It tells the patient whether a specific option is realistic before a visa, flights and a hotel are booked.
What a Lung Cancer Consultation in China Should Answer
A useful consultation ends with clear answers to five questions:
Does the tumour's biomarker profile match any option that is approved in China but not available at home?
Is surgery, ablation or radiotherapy possible for this tumour, given its size, location and the patient's age?
Are new tests needed in China, and how long would they take?
How long would the patient need to stay in China, and how often must they return?
If a long-term drug is recommended, how will it be continued and monitored after the patient goes home?
The last question matters most for targeted drugs and immunotherapy, which are often taken for months or years.
Case Studies: Two International Lung Cancer Patients
An EGFR-Mutated Lung Cancer Patient From New Zealand
Rachel M. (alias) had EGFR-mutated lung adenocarcinoma and had completed two courses of platinum-based chemotherapy in New Zealand, after which no further options remained locally. In China she started amivantamab, an EGFR-targeted therapy, and learned of sunvozertinib, another EGFR-targeted drug available in China but not yet approved in New Zealand. Her story is told in full in this EGFR-mutated lung cancer case study.
A 74-Year-Old Indonesian Patient Considered Too High-Risk for Surgery
Arif Santoso (alias) had a 4.7 cm lung adenocarcinoma near major blood vessels, and local doctors judged surgery too risky. At a licensed oncology hospital in Guangzhou, China, a multidisciplinary team planned bronchial artery chemoembolisation followed by CT-guided cryoablation. One week after the arterial treatment the tumour had shrunk to 37.5 mm, and after cryoablation he was out of bed the next day with a much-improved cough. The full account is in this lung cancer cryoablation case.
Both cases began the same way: a specialist review of imaging and pathology before any treatment decision.
How International Patients Can Book a Lung Cancer Consultation in China
1. Through ChinaCureLink, the dedicated international patient pathway. ChinaCureLink represents the patient, not any hospital, and takes no hospital commission. There is no fee to apply to hospitals. After a free advisory call, ChinaCureLink identifies and compares up to three suitable hospitals or lung cancer specialists. The patient chooses one, and ChinaCureLink arranges a video second opinion with that specialist before any travel. If the patient proceeds, ChinaCureLink coordinates the appointment, record translation, hospital communication, treatment planning, travel and support in China. More detail is in how ChinaCureLink matches patients with hospitals.
2. Through a hospital's international medical department. Several major hospitals, such as Peking Union Medical College Hospital, run international services with English-language booking. These departments mainly serve foreigners living in or visiting China, and usually expect the patient to attend in person.
3. Through a home oncologist's professional network. Some oncologists have academic contacts in China and can request an informal opinion, although this rarely includes appointment booking or travel support.
Patients with other cancer types can use the same steps; ChinaCureLink's guide on how to book an oncology appointment in China covers them.
What to Expect When Booking a Chinese Hospital Directly
Booking directly is possible, but international patients usually meet several practical limits:
Registration systems built for residents. At Sun Yat-sen University Cancer Center, outpatient visits are by appointment only, booked through the hospital app or WeChat, and registration requires a Chinese mobile number.
Chinese payment apps. The same hospital's app and WeChat account accept only WeChat Pay or Alipay.
Records in Chinese only. Test results, reports and discharge summaries are issued in Chinese, and many hospitals do not provide translation.
Short outpatient slots. Standard outpatient visits are brief, which leaves little time to review a complex history through an interpreter.
No pre-travel answer. Without a records review beforehand, the patient may travel only to learn that a test must be repeated or an option does not apply.
For these reasons, most international lung cancer patients secure a specialist's opinion on their records first and travel second.
ChinaCureLink replies to new case enquiries within 10 minutes. A preliminary case review checks the patient's records against what Chinese lung cancer teams can offer, then outlines up to three suitable hospitals or specialists.
You may also like:
Get a Second Opinion
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Can a foreigner book a lung cancer consultation in China?
Yes. Chinese hospitals see international patients, and leading cancer centres have international departments. The main hurdles are booking systems that need a Chinese phone number or payment app, and records issued only in Chinese, which a facilitator such as ChinaCureLink can handle.
Can a Chinese lung cancer specialist review my case online before I travel?
Yes, as a records-based second opinion. China's rules do not allow a first diagnosis online, so the specialist gives an opinion on options based on translated records and imaging, and the hospital confirms the plan in person.
What records do I need for a lung cancer consultation in China?
The pathology report, a full molecular report (EGFR, ALK, ROS1, MET, KRAS, RET, PD-L1), recent CT or PET-CT images, a brain MRI, a dated treatment history and recent blood tests.
How long does it take to book a lung cancer consultation in China?
It depends mainly on how complete the records are. With translated records and imaging ready, a video second opinion can often be arranged within days to a few weeks; missing molecular tests are the most common cause of delay.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
ASCO Post. Ivonescimab significantly improves overall survival vs pembrolizumab in PD-L1–positive advanced NSCLC, September 2026. https://ascopost.com/news/september-2026/ivonescimab-significantly-improves-overall-survival-vs-pembrolizumab-in-pd-l1-positive-advanced-nsclc/
Han B, et al. Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center, 2024. https://pubmed.ncbi.nlm.nih.gov/39036382/
ASCO Post. Adjuvant osimertinib in resected EGFR-mutant NSCLC: overall survival analysis of the ADAURA trial, July 2023. https://ascopost.com/news/july-2023/adjuvant-osimertinib-in-resected-egfr-mutant-nsclc-overall-survival-analysis-of-the-adaura-trial/
Shi Y, et al. Furmonertinib versus gefitinib in EGFR-mutated NSCLC (FURLONG). Lancet Respiratory Medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/35662408/
Sun Yat-sen University Cancer Center. A Guide for International Patients. https://english.sysucc.org.cn/index_24.aspx
Peking Union Medical College Hospital. Foreign Patients Seeking Medical Treatment. https://www.pumch.cn/en/detail/43295.html
Ropes & Gray. China's Health Authorities Issue New Rules on Telemedicine, 2018. https://www.ropesgray.com/en/newsroom/alerts/2018/09/Chinas-Health-Authorities-Issue-New-Rules-on-Telemedicine
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
